Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bevan

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Science (New York, N.Y.)|June 6, 1998
Mutations in the SMAD4/DPC4 gene in juvenile polyposisJ R Howe, S Roth, J C Ringold, et al.
Clinical Endocrinology|September 26, 2007
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effectiveJ S Bevan, J Newell-Price, J A H Wass, et al.
Cancer Research|May 16, 2000
Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epitheliumK Woodford-Richens, J Williamson, S Bevan, et al.
Nephron. Physiology|November 29, 2008
The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney developmentHeather S Bevan, Nynke M S van den Akker, Yan Qiu, et al.
International Journal of Pediatric Endocrinology|March 18, 2016
An audit of the management of childhood-onset growth hormone deficiency during young adulthood in ScotlandM Ahmid, V Fisher, A J Graveling, et al.
Gut|August 14, 1999
Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndromeS Bevan, K Woodford-Richens, P Rozen, et al.
Human Molecular Genetics|November 13, 1998
Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of casesR Houlston, S Bevan, A Williams, et al.
Leukemia|October 12, 1999
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemiaS Bevan, D Catovsky, A Marossy, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor sizeJ S Bevan, S L Atkin, A B Atkinson, et al.
Cancer Research|November 3, 2004
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expressionJeanette Woolard, Wen-Ying Wang, Heather S Bevan, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Science (New York, N.Y.)|June 6, 1998
Mutations in the SMAD4/DPC4 gene in juvenile polyposisJ R Howe, S Roth, J C Ringold, et al.
Clinical Endocrinology|September 26, 2007
Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effectiveJ S Bevan, J Newell-Price, J A H Wass, et al.
Cancer Research|May 16, 2000
Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epitheliumK Woodford-Richens, J Williamson, S Bevan, et al.
Nephron. Physiology|November 29, 2008
The alternatively spliced anti-angiogenic family of VEGF isoforms VEGFxxxb in human kidney developmentHeather S Bevan, Nynke M S van den Akker, Yan Qiu, et al.
International Journal of Pediatric Endocrinology|March 18, 2016
An audit of the management of childhood-onset growth hormone deficiency during young adulthood in ScotlandM Ahmid, V Fisher, A J Graveling, et al.
Gut|August 14, 1999
Screening SMAD1, SMAD2, SMAD3, and SMAD5 for germline mutations in juvenile polyposis syndromeS Bevan, K Woodford-Richens, P Rozen, et al.
Human Molecular Genetics|November 13, 1998
Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of casesR Houlston, S Bevan, A Williams, et al.
Leukemia|October 12, 1999
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemiaS Bevan, D Catovsky, A Marossy, et al.
The Journal of Clinical Endocrinology and Metabolism|October 5, 2002
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor sizeJ S Bevan, S L Atkin, A B Atkinson, et al.
Cancer Research|November 3, 2004
VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expressionJeanette Woolard, Wen-Ying Wang, Heather S Bevan, et al.
Pageof 24